c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
Contents:; Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome -- Special considerations for ICU management of patients r…
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
c.1 BC Cancer Agency VAN Library AV Room | Available |
Introduction; RANK ligand in bone biology; Bone metastases; Multiple myeloma; Skeletal-related events (SREs); Hormone ablative therapy-induced bone loss
c.1 BC Cancer Agency ARHCC Library | Available |